<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Peptides Hereditary angioedema Pharmacology Angioedema Non-steroidal anti-inflammatory drugs C1-inhibitor Icatibant Ecallantide Jerini Health Complement deficiency Medicine |
Add to Reading List |
Longhurst et al. Allergy, Asthma & Clinical Immunology 2010, 6:22 http://www.aacijournal.com/contentREVIEW ALLERGY, ASTHMA & CLINICAL![[Product Monograph Template - Schedule D]](https://www.pdfsearch.io/img/2c69a54785549922aec5fc16f385365b.jpg "[Product Monograph Template - Schedule D]") | [Product Monograph Template - Schedule D]DocID: 1qWQL - View Document |
 | News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web SitesDocID: 1qHpD - View Document |
 | Microsoft Word - CINRYZE.Product MonographdocDocID: 1qE2h - View Document |
 | Microsoft Word - FIRAZYR.Product MonographdocDocID: 1qA9x - View Document |
 | Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we developDocID: 1pVHk - View Document |